Tenax Therapeutics (TENX) Long-Term Debt Repayments (2010 - 2024)
Tenax Therapeutics recorded quarterly Long-Term Debt Repayments of $279000.0 in Q3 2024, up 108.21% quarter-over-quarter from $134000.0 in Q2 2024, and up 62.89% year-over-year from $171283.0 in Q4 2023.
Tenax Therapeutics' Long-Term Debt Repayments history runs 9 years deep, the most recent figure standing at $279000.0 for Q3 2024.
- In Q3 2024, Long-Term Debt Repayments rose 62.89% year-over-year to $279000.0; the TTM figure through Jun 2025 stood at $279000.0 (down 50.83% YoY), while the FY2024 annual figure was $501000.0, down 19.71% from the prior year.
- Long-Term Debt Repayments came in at $279000.0 for Q3 2024 at Tenax Therapeutics, up from $134000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $279000.0 in Q3 2024 to a low of -$364546.0 in Q4 2022.
- A 3-year average of $102272.7 and a median of $135784.0 in 2022 frame the typical range for Long-Term Debt Repayments.
- Across the five-year window, Long-Term Debt Repayments jumped 147.78% in 2023 and dropped 20.31% in 2024, its largest moves.
- Tenax Therapeutics' Long-Term Debt Repayments stood at -$364546.0 in 2022, then surged by 147.78% to $174164.0 in 2023, then jumped by 60.19% to $279000.0 in 2024.
- According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $279000.0, $134000.0, and $88000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 279,000.00 |
| Sep 30, 2024 | 279,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 174,164.00 |
| Dec 31, 2023 | 174,164.00 |
| Sep 30, 2023 | 171,283.00 |
| Sep 30, 2023 | 171,283.00 |
| Jun 30, 2023 | 168,157.00 |
| Jun 30, 2023 | 168,157.00 |
| Mar 31, 2023 | 110,396.00 |
| Mar 31, 2023 | 110,396.00 |
| Dec 31, 2022 | -364,546.00 |
| Dec 31, 2022 | -364,546.00 |
| Sep 30, 2022 | 91,875.00 |
| Sep 30, 2022 | 91,875.00 |
| Jun 30, 2022 | 136,887.00 |
| Jun 30, 2022 | 136,887.00 |
| Mar 31, 2022 | 135,784.00 |
| Mar 31, 2022 | 135,784.00 |
| Dec 31, 2015 | 100,160.00 |
| Dec 31, 2015 | 100,160.00 |
| Sep 30, 2015 | 48,209.00 |
| Sep 30, 2015 | 48,209.00 |
| Jun 30, 2015 | -245,010.00 |
| Jun 30, 2015 | -245,010.00 |
| Jul 31, 2014 | 347,561.00 |
| Jul 31, 2014 | 347,561.00 |
| Apr 30, 2014 | 46,876.00 |
| Apr 30, 2014 | 46,876.00 |
| Jan 31, 2014 | 30,876.00 |
| Jan 31, 2014 | 30,876.00 |
| Oct 31, 2013 | 23,167.00 |
| Oct 31, 2013 | 23,167.00 |
| Jul 31, 2013 | 34,372.00 |
| Jul 31, 2013 | 34,372.00 |
| Apr 30, 2013 | 100,895.00 |
| Apr 30, 2013 | 100,895.00 |
| Jan 31, 2013 | -55,763.00 |
| Jan 31, 2013 | -55,763.00 |
| Oct 31, 2012 | 14,027.00 |
| Oct 31, 2012 | 14,027.00 |
| Jul 31, 2012 | 41,736.00 |
| Jul 31, 2012 | 41,736.00 |
| Jan 31, 2012 | 7.96 Mn |
| Jan 31, 2012 | 7.96 Mn |
| Oct 31, 2011 | 8,630.00 |
| Oct 31, 2011 | 8,630.00 |
| Jul 31, 2011 | 27,470.00 |
| Jul 31, 2011 | 27,470.00 |
| Apr 30, 2011 | -77,312.00 |
| Apr 30, 2011 | -77,312.00 |
| Jan 31, 2011 | 127,153.00 |
| Jan 31, 2011 | 127,153.00 |
| Oct 31, 2010 | -19,936.00 |
| Oct 31, 2010 | -19,936.00 |
| Jul 31, 2010 | -29,905.00 |
| Jul 31, 2010 | -29,905.00 |